Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clinical significance of cytomegalovirus reactivation in patients with plasma cell dyscrasia who were treated with anti-CD38 monoclonal antibody: A retrospective analysis in a single institution
Anti-CD38 monoclonal antibodies (mAbs) have improved the prognosis of patients with plasma cell dyscrasia (PCD), but are also associated with increased infectious adverse events. Cytomegalovirus (CMV) is a common latent pathogen that is reactivated in immunocompromised individuals. Although CMV reactivation has mostly been reported after high-dose chemotherapy followed by stem cell transplantation in patients with PCD, cases of reactivation during anti-CD38 mAb therapy have been reported recently. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 30, 2024 Category: Hematology Authors: Naohiro Matsunaga, Tomotaka Suzuki, Nozomi Nishitarumizu, Yoko Nakanishi, Aki Kondo, Yukiyasu Kato, Toru Ebina, Yoshiaki Marumo, Tomoyuki Nakamura, Takahiro Nakashima, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuk Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 28, 2024 Category: Hematology Source Type: research

Mantle Cell Lymphoma under the scope of personalized medicine: perspective and directions
Mantle Cell Lymphoma (MCL) is a rare, incurable non-Hodgkin's lymphoma characterized by naive B cells infiltrating the lymphoid follicle's mantle zone. A key feature of MCL is the cytogenetic abnormality t(11;14) (q13:q14), found in 95% of cases, leading to Cyclin D1 overexpression resulting in uncontrolled cell cycle progression and genetic instability. Occasionally, Cyclin D2 or D3 overexpression can substitute for Cyclin D1, causing similar effects. The transcription factor SOX11 is a hallmark of classical Cyclin D1-positive MCL and also in cases without the typical t(11;14) abnormality, making it an important diagnosti...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 27, 2024 Category: Hematology Authors: Lara Gallucci Figorelle, Peterson Tiago Galv ão, Felipe Matheus Ribeiro de Lima, Patricia Marimon, Nathalia Pentagna, Cristiane Milito, Rony Schaffel, Katia Carneiro Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions | Pre-emptive Therapy at Molecular Measurable Residual Disease Failure in Acute Myeloid Leukaemia
Molecular measurable residual disease (MRD, e.g., by real-time quantitative polymerase chain reaction, RT-qPCR), is an integral part of response assessment in acute myeloid leukaemia (AML) with established prognostic and evolving therapeutic significance. MRD failure can occur through several pathways (namely MRD persistence at the end of treatment at a high level, MRD progression from a low level or MRD re-emergence during follow up; the latter two constitute MRD relapse as defined by the European Leukaemia Net) and is clinically actionable, with survival benefit reported in AML subgroups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 26, 2024 Category: Hematology Authors: Aditya Tedjaseputra, Nigel Russell, Richard Dillon Source Type: research

Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting
Immunotherapeutic strategies, specifically T-cell redirected therapies have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment se...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 21, 2024 Category: Hematology Authors: Noopur S. Raje, Adam D Cohen, Krina K Patel, Niels W.C.J. van de Donk, Joshua Richter, Jesus San-Miguel Source Type: research

SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes
Higher-risk myelodysplastic syndromes (HR-MDS) are clonal myeloid neoplasms that cause life-limiting complications from severe cytopenias and leukemic transformation. Efforts to better classify, prognosticate, and assess therapeutic responses in HR-MDS have resulted in publication of new clinical tools in the last several years. Given limited current treatment options and suboptimal outcomes, HR-MDS stands to benefit from the study of investigational agents. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Tags: Review Article Source Type: research

Characteristics and outcomes of patients with relapsed/refractory multiple myeloma after exposure to lenalidomide in first line of therapy: a single center database review in greece
Most patients with multiple myeloma (MM) will develop disease recurrence during first-line (1L) treatment and eventually to subsequent treatments. These patients become refractory to treatment (developing relapsed/refractory MM [RRMM]), with disease severity and duration of remission worsening with each successive relapse.1, 2 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Efstathios Kastritis, Ioannis Ntanasis-Stathopoulos, Foteini Theodorakakou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Despina Fotiou, Vassiliki Spiliopoulou, Maria Gavriatopoulou, Sach Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions | An Update on Higher Risk Myelodysplastic Syndromes
High-risk myelodysplastic neoplasms (abbreviated HR-MDS) are a heterogenous group of clonal myeloid-lineage malignancies often characterized by high-risk genetic lesions, increased blood transfusion needs, constitutional symptoms, elevated risk of progression to acute myeloid leukemia (AML) and therapeutic need for bone marrow transplantation. Use of blast percentage and other morphologic features to define MDS subtypes is rapidly shifting to incorporate genetics, resulting in a subset of former HR-MDS patients now being considered as AML in presence of leukemia-defining genetic alterations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Michael J. Hochman, Amy E. DeZern Source Type: research

SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
The field of Cellular Immunotherapy has rapidly evolved over the past decade. Since the first Food and Drug Administration (FDA) approval of tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) in 2017, the list of approvals expanded to include brexucabtagene autoleucel (Tecartus) in 2020, lisocabtagene maraleucel (Breyanzi) in 2021, idacabtagene vicleucel (Abecma) in 2021, and ciltacabtagene autoleucel (Carvykti) in 2022.1-9 In addition, cellular therapies are being studied earlier in the treatment course for patients with relapsed lymphoma and multiple myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 18, 2024 Category: Hematology Authors: Timothy J Voorhees, Evandro Bezerra, Nathan Denlinger, Samantha Jaglowski, Marcos de Lima Source Type: research

BCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma
A 53-year-old man with relapsed multiple myeloma presented with bilateral upper limb sensorimotor symptoms caused by an enlarging cervical spine (C3) tumoral lesion. His prior treatments included spinal surgery and radiotherapy (RT) 11 years earlier for solitary plasmacytoma, daratumumab bortezomib lenalidomide dexamethasone followed by high dose melphalan and autologous stem-cell transplantation and daratumumab + lenalidomide maintenance as first line therapy for systemic myeloma 4 years before current presentation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Chandramouli Nagarajan, Martin Wong Eu Jo, Thomas G Martin Tags: Letter to the Editor Source Type: research

SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Timothy Schmidt, Zhubin Gahvari, Natalie S. Callander Tags: Review Article Source Type: research

BCMA directed Bispecific Antibody induced tumour flare in Multiple Myeloma
Bispecific antibodies have emerged as highly effective treatments for multiple myeloma patients even in late relapse when all available novel agents have been exhausted. However, they cause some adverse events of special interest (AESI) that treating physicians need to be aware of. AESIs like CRS and ICANS are reasonably wellcaptured and reported in most early phase and pivotal studies and their management strategies have been well discussed, debated, and published. However, tumour flare reactions caused by BsAb induced T-cell activation and associated inflammatory reaction have hardly been reported in the pivotal trials o...
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Dr. Chandramouli Nagarajan, Dr. Thomas G Martin Tags: Letter to the Editor Source Type: research

SOHO State of the Art Updates and Next Questions | Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Monoclonal proteins are common, with a prevalence in the United States around 5% and the incidence increases with age. Although most patients are asymptomatic, the vast majority of cases are caused by a clonal plasma cell disorder. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) are asymptomatic precursor conditions with variable risk of progression to multiple myeloma (MM). In recent years, significant progress has been made to better understand the factors that lead to the development of symptoms and progression to myeloma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 16, 2024 Category: Hematology Authors: Timothy Schmidt, Zhubin Gahvari, Natalie S. Callander Source Type: research

Average Temperature as a Marker of Lymphoma-Associated HLH
Peak temperature, and 12-hour mean temperature were analysed in lymphoma patients presenting with a significantly raised serum ferritin. 12 (out of 23) patients were found to have hemophagocytic lymphohistiocytosis (HLH). 12-hour temperature proved a better predictor of HLH than peak temperature in this cohort, which has highlighted the need for further research into this simple clinical parameter. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - March 10, 2024 Category: Hematology Authors: Cameron Clark, Jack Goddard, Rachel Tattersall, Nick Morley Tags: Original Study Source Type: research